Weekly Research Analysts’ Ratings Updates for Theravance Biopharma (TBPH)

Theravance Biopharma (NASDAQ: TBPH) recently received a number of ratings updates from brokerages and research firms:

• 3/5/2026 – Theravance Biopharma was downgraded by Oppenheimer Holdings, Inc. from “outperform” to “market perform”.
• 3/4/2026 – Theravance Biopharma had its “neutral” rating reaffirmed by B. Riley Financial, Inc.. They now have a $14.00 price target on the stock, down from $28.00.
• 3/3/2026 – Theravance Biopharma had its price target lowered by BTIG Research from $40.00 to $21.00. They now have a “buy” rating on the stock.
• 3/2/2026 – Theravance Biopharma had its price target raised by HC Wainwright from $20.00 to $27.00. They now have a “buy” rating on the stock.
• 2/3/2026 – Theravance Biopharma had its “buy” rating reaffirmed by BTIG Research. They now have a $40.00 price target on the stock.
• 1/22/2026 – Theravance Biopharma had its “hold (c)” rating reaffirmed by Weiss Ratings.

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.